This research suggests that lung cancer cells may exhibit varying susceptibilities to the synergistic effects of PARP inhibitors and cisplatin in chemosensitization (Ji et al., 2020; Stolzenburg et al., 2022; Diéras et al., 2020). This evidence concerns the gene PARP1 and lung cancer.